PT1362047E - Compostos de pirrolina substituidos com indazolilo como inibidores de cinase - Google Patents
Compostos de pirrolina substituidos com indazolilo como inibidores de cinaseInfo
- Publication number
- PT1362047E PT1362047E PT01990971T PT01990971T PT1362047E PT 1362047 E PT1362047 E PT 1362047E PT 01990971 T PT01990971 T PT 01990971T PT 01990971 T PT01990971 T PT 01990971T PT 1362047 E PT1362047 E PT 1362047E
- Authority
- PT
- Portugal
- Prior art keywords
- indazolyl
- kinase inhibitors
- kinase
- substituted pyrroline
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25416600P | 2000-12-08 | 2000-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1362047E true PT1362047E (pt) | 2006-09-29 |
Family
ID=22963185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT01990971T PT1362047E (pt) | 2000-12-08 | 2001-12-06 | Compostos de pirrolina substituidos com indazolilo como inibidores de cinase |
Country Status (26)
Country | Link |
---|---|
US (4) | US6849643B2 (pt) |
EP (1) | EP1362047B1 (pt) |
JP (1) | JP2004515499A (pt) |
KR (1) | KR20040016828A (pt) |
CN (1) | CN1230434C (pt) |
AT (1) | ATE326464T1 (pt) |
AU (1) | AU2002230727A1 (pt) |
BR (1) | BR0116468A (pt) |
CA (1) | CA2431166A1 (pt) |
CY (1) | CY1106125T1 (pt) |
CZ (1) | CZ20031594A3 (pt) |
DE (1) | DE60119790T2 (pt) |
DK (1) | DK1362047T3 (pt) |
ES (1) | ES2263681T3 (pt) |
HK (1) | HK1057370A1 (pt) |
HU (1) | HUP0303855A3 (pt) |
IL (1) | IL156339A0 (pt) |
MX (1) | MXPA03005140A (pt) |
NO (1) | NO20032625L (pt) |
NZ (1) | NZ526356A (pt) |
PL (1) | PL362576A1 (pt) |
PT (1) | PT1362047E (pt) |
RU (1) | RU2003117078A (pt) |
WO (1) | WO2002046183A2 (pt) |
YU (1) | YU46603A (pt) |
ZA (1) | ZA200305239B (pt) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA03005140A (es) * | 2000-12-08 | 2004-10-15 | Johnson & Johnson | Compuestos de pirrolina sustituidos con indazolilo como inhibidores de cinasa. |
JP2005508365A (ja) * | 2001-10-29 | 2005-03-31 | ネクター セラピューティックス エイエル,コーポレイション | プロテインキナーゼcインヒビターのポリマー結合体 |
JP4414232B2 (ja) | 2002-03-05 | 2010-02-10 | イーライ リリー アンド カンパニー | キナーゼ阻害物質 |
DE60315270T2 (de) | 2002-03-08 | 2008-04-17 | Eli Lilly And Co., Indianapolis | Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren |
AU2003225295A1 (en) * | 2002-05-08 | 2003-11-11 | Janssen Pharmaceutica N.V. | Substituted pyrroline kinase inhibitors |
DE60323749D1 (de) * | 2002-06-05 | 2008-11-06 | Janssen Pharmaceutica Nv | Substituierte pyrroline als kinase inhibitoren |
JP2006521386A (ja) * | 2003-03-27 | 2006-09-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キナーゼ阻害剤である置換ピロリン |
RS20050915A (sr) * | 2003-06-13 | 2008-04-04 | Janssen Pharmaceutica N.V., | Supstituisani derivati indazolil (indolil)maleimida kao inhibitori kinaze |
CA2530679A1 (en) * | 2003-06-30 | 2005-04-07 | Hif Bio, Inc. | Compounds for treating angiogenesis |
EP1664294A2 (en) * | 2003-09-19 | 2006-06-07 | Children's Hospital Medical Center | Regulation of cardiac contractility and heart failure propensity |
EP1667979A4 (en) * | 2003-09-23 | 2007-04-18 | Merck & Co Inc | INHIBITORS OF POTASSIUM CHANNELS WITH ISOQUINOLINE |
JP2008520592A (ja) * | 2004-11-23 | 2008-06-19 | インターナショナル・バイオ−セラピューティック・リサーチ・インコーポレイテッド | 治療用金属イオン、合金、および塩の輸送方法 |
US8017395B2 (en) | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
SE0500055D0 (sv) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
US7582629B2 (en) | 2005-01-10 | 2009-09-01 | Astrazeneca Ab | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators |
SE0500058D0 (sv) * | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 5 |
US20090306107A1 (en) * | 2005-03-17 | 2009-12-10 | Novartis Ag | Organic Compounds |
PT1888123E (pt) | 2005-06-08 | 2013-03-13 | Janssen Biotech Inc | Uma terapêutica celular para a degeneração ocular |
WO2007008514A2 (en) * | 2005-07-07 | 2007-01-18 | Georgetown University | Inhibitors of glycogen synthase kinase 3 |
WO2007041195A2 (en) * | 2005-09-29 | 2007-04-12 | Janssen Pharmaceutica N.V. | Macroheterocylic compounds as kinase inhibitors |
US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
WO2007143119A2 (en) * | 2006-06-01 | 2007-12-13 | The Board Of Trustees Of The Leland Stanford Junior University | Method of preventing progression of hypertension-induced heart failure with pkc peptides |
ES2446269T3 (es) | 2006-12-19 | 2014-03-06 | The Board Of Trustees Of The University Of Illinois | 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos |
AU2008216382A1 (en) * | 2007-02-12 | 2008-08-21 | Array Biopharma, Inc. | Novel inhibitors hepatitis C virus replication |
US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
MX2010001335A (es) | 2007-07-31 | 2010-06-02 | Lifescan Inc | Diferenciacion de celulas madre embrionarias humanas. |
BRPI0819609A2 (pt) | 2007-11-27 | 2014-10-14 | Lifescan Inc | Diferenciação de células-tronco embrionárias de ser humano |
AU2009215516B2 (en) | 2008-02-21 | 2014-12-18 | Janssen Biotech Inc. | Methods, surface modified plates and compositions for cell attachment, cultivation and detachment |
US8623648B2 (en) * | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
KR20180018839A (ko) | 2008-06-30 | 2018-02-21 | 얀센 바이오테크 인코포레이티드 | 만능 줄기 세포의 분화 |
CN102333862B (zh) | 2008-10-31 | 2018-04-27 | 詹森生物科技公司 | 人胚胎干细胞向胰腺内分泌谱系的分化 |
BRPI0919885A2 (pt) | 2008-10-31 | 2015-08-11 | Centocor Ortho Biotech Inc | Diferenciação de células-tronco embrionárias humanas para a linhagem endócrina pancreática |
KR101687344B1 (ko) | 2008-11-20 | 2016-12-16 | 얀센 바이오테크 인코포레이티드 | 평면 기재상의 세포 부착 및 배양을 위한 방법 및 조성물 |
MX356756B (es) | 2008-11-20 | 2018-06-11 | Centocor Ortho Biotech Inc | Células madre pluripotentes en microportadores. |
KR20170118969A (ko) | 2009-07-20 | 2017-10-25 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
EP2456859A4 (en) | 2009-07-20 | 2015-03-18 | Janssen Biotech Inc | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS |
PL2456858T3 (pl) | 2009-07-20 | 2019-01-31 | Janssen Biotech, Inc | Różnicowanie ludzkich embrionalnych komórek macierzystych |
PL2516626T3 (pl) | 2009-12-23 | 2017-10-31 | Janssen Biotech Inc | Różnicowanie ludzkich zarodkowych komórek macierzystych |
EP2516625B1 (en) | 2009-12-23 | 2024-06-26 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
AU2011223900A1 (en) | 2010-03-01 | 2012-09-13 | Janssen Biotech, Inc. | Methods for purifying cells derived from pluripotent stem cells |
WO2011143430A1 (en) | 2010-05-12 | 2011-11-17 | Abbott Laboratories | Indazole inhibitors of kinase |
CN102884176B (zh) | 2010-05-12 | 2017-09-05 | 詹森生物科技公司 | 人胚胎干细胞的分化 |
BR112013004616A2 (pt) | 2010-08-31 | 2016-07-05 | Janssen Biotech Inc | diferenciação das células tronco embrionárias humanas |
AU2011296383B2 (en) | 2010-08-31 | 2016-03-10 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells |
EP3211070A1 (en) | 2010-08-31 | 2017-08-30 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
CA2860107C (en) | 2011-12-22 | 2021-06-01 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into single hormonal insulin positive cells |
CA2866590A1 (en) | 2012-03-07 | 2013-09-12 | Janssen Biotech, Inc. | Defined media for expansion and maintenance of pluripotent stem cells |
CN108103006A (zh) | 2012-06-08 | 2018-06-01 | 詹森生物科技公司 | 人胚胎干细胞向胰腺内分泌细胞的分化 |
WO2014090398A1 (en) * | 2012-12-10 | 2014-06-19 | Centogene Ag | Use of maleimide derivatives for preventing and treating leukemia |
SG10201707811XA (en) | 2012-12-31 | 2017-11-29 | Janssen Biotech Inc | Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators |
ES2837763T3 (es) | 2012-12-31 | 2021-07-01 | Janssen Biotech Inc | Cultivo de células madre embrionarias humanas en la interconexión aire-líquido para la diferenciación en células endocrinas pancreáticas |
US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
SG10201709384SA (en) | 2012-12-31 | 2018-01-30 | Janssen Biotech Inc | Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells |
SG10201810739VA (en) | 2014-05-16 | 2019-01-30 | Janssen Biotech Inc | Use of small molecules to enhance mafa expression in pancreatic endocrine cells |
GB201509885D0 (en) * | 2015-06-08 | 2015-07-22 | Ucb Biopharma Sprl | Therapeutic agents |
MA45479A (fr) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen |
US10383881B2 (en) | 2016-12-30 | 2019-08-20 | Frequency Therapeutics, Inc. | 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same |
MX2019007890A (es) | 2016-12-30 | 2020-01-20 | Frequency Therapeutics Inc | Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte. |
EA202190952A1 (ru) | 2018-10-05 | 2021-12-22 | Аннапурна Байо, Инк. | Соединения и композиции для лечения патологических состояний, связанных с активностью рецептора apj |
EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
KR20220156535A (ko) | 2020-02-07 | 2022-11-25 | 가셔브룸 바이오, 인크. | 헤테로사이클릭 glp-1 작용제 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ227850A (en) * | 1988-02-10 | 1991-11-26 | Hoffmann La Roche | Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders |
MC2096A1 (fr) | 1989-02-23 | 1991-02-15 | Hoffmann La Roche | Pyrroles substitues |
GB8904161D0 (en) | 1989-02-23 | 1989-04-05 | Hoffmann La Roche | Substituted pyrroles |
DE4005969A1 (de) | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
DE4005970A1 (de) | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
US5624949A (en) | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
ATE456367T1 (de) | 1993-12-23 | 2010-02-15 | Lilly Co Eli | Proteinkinase c inhibitoren |
SE9603283D0 (sv) | 1996-09-10 | 1996-09-10 | Astra Ab | New compounds |
AU2548699A (en) | 1998-02-23 | 1999-09-06 | Rei Asakai | Cell death inhibitors |
CA2338866A1 (en) | 1998-07-30 | 2000-02-10 | Japan Tobacco Inc. | Disubstituted maleimide compound and pharmaceutical use thereof |
JP2002527419A (ja) * | 1998-10-08 | 2002-08-27 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Gsk−3阻害物質としてのピロール−2,5−ジオン類 |
MXPA03005140A (es) * | 2000-12-08 | 2004-10-15 | Johnson & Johnson | Compuestos de pirrolina sustituidos con indazolilo como inhibidores de cinasa. |
AU2003225295A1 (en) * | 2002-05-08 | 2003-11-11 | Janssen Pharmaceutica N.V. | Substituted pyrroline kinase inhibitors |
DE60323749D1 (de) * | 2002-06-05 | 2008-11-06 | Janssen Pharmaceutica Nv | Substituierte pyrroline als kinase inhibitoren |
CA2488602A1 (en) * | 2002-06-05 | 2003-12-18 | Janssen Pharmaceutica N.V. | Substituted pyrrolines as kinase inhibitors |
JP2006521386A (ja) * | 2003-03-27 | 2006-09-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キナーゼ阻害剤である置換ピロリン |
RS20050915A (sr) * | 2003-06-13 | 2008-04-04 | Janssen Pharmaceutica N.V., | Supstituisani derivati indazolil (indolil)maleimida kao inhibitori kinaze |
-
2001
- 2001-12-06 MX MXPA03005140A patent/MXPA03005140A/es active IP Right Grant
- 2001-12-06 IL IL15633901A patent/IL156339A0/xx unknown
- 2001-12-06 CA CA002431166A patent/CA2431166A1/en not_active Abandoned
- 2001-12-06 DE DE60119790T patent/DE60119790T2/de not_active Expired - Fee Related
- 2001-12-06 RU RU2003117078/04A patent/RU2003117078A/ru not_active Application Discontinuation
- 2001-12-06 HU HU0303855A patent/HUP0303855A3/hu unknown
- 2001-12-06 NZ NZ526356A patent/NZ526356A/xx unknown
- 2001-12-06 BR BR0116468-6A patent/BR0116468A/pt not_active IP Right Cessation
- 2001-12-06 DK DK01990971T patent/DK1362047T3/da active
- 2001-12-06 KR KR10-2003-7007710A patent/KR20040016828A/ko not_active Application Discontinuation
- 2001-12-06 US US10/013,181 patent/US6849643B2/en not_active Expired - Lifetime
- 2001-12-06 JP JP2002547921A patent/JP2004515499A/ja not_active Ceased
- 2001-12-06 ES ES01990971T patent/ES2263681T3/es not_active Expired - Lifetime
- 2001-12-06 PL PL01362576A patent/PL362576A1/xx not_active Application Discontinuation
- 2001-12-06 CN CNB018225675A patent/CN1230434C/zh not_active Expired - Fee Related
- 2001-12-06 EP EP01990971A patent/EP1362047B1/en not_active Expired - Lifetime
- 2001-12-06 CZ CZ20031594A patent/CZ20031594A3/cs unknown
- 2001-12-06 AU AU2002230727A patent/AU2002230727A1/en not_active Abandoned
- 2001-12-06 YU YU46603A patent/YU46603A/sh unknown
- 2001-12-06 PT PT01990971T patent/PT1362047E/pt unknown
- 2001-12-06 AT AT01990971T patent/ATE326464T1/de not_active IP Right Cessation
- 2001-12-06 WO PCT/US2001/047689 patent/WO2002046183A2/en active IP Right Grant
-
2003
- 2003-06-10 NO NO20032625A patent/NO20032625L/no not_active Application Discontinuation
- 2003-07-07 ZA ZA200305239A patent/ZA200305239B/en unknown
-
2004
- 2004-01-12 HK HK04100221A patent/HK1057370A1/xx not_active IP Right Cessation
- 2004-07-06 US US10/885,373 patent/US7304060B2/en not_active Expired - Fee Related
- 2004-08-02 US US10/909,537 patent/US7329657B2/en not_active Expired - Fee Related
-
2006
- 2006-07-21 CY CY20061101017T patent/CY1106125T1/el unknown
-
2007
- 2007-12-13 US US12/001,805 patent/US7855203B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1362047E (pt) | Compostos de pirrolina substituidos com indazolilo como inibidores de cinase | |
WO2003103663A3 (en) | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | |
DE60319364D1 (de) | Substituierte pyrroline als kinase inhibitoren | |
AU2737102A (en) | Macroheterocylic compounds useful as kinase inhibitors | |
RS20050915A (sr) | Supstituisani derivati indazolil (indolil)maleimida kao inhibitori kinaze | |
AU3741801A (en) | Substituted beta-carbolines with ikb-kinase inhibiting activity | |
YU84603A (sh) | Novi inhibitori tirozin kinaze | |
BG106585A (en) | Kinase inhibitors as therapeutic agents | |
AU5584901A (en) | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease | |
MXPA03011907A (es) | Fluoropirrolidinas como inhibidores de dipeptidil peptidasa. | |
EA200400006A1 (ru) | Бензоилсульфонамиды и сульфонилбензамидины для применения в качестве противоопухолевых агентов | |
NZ508268A (en) | Bicyclic pyrimidines and bicyclic 3,4- dihydropyrimidines as inhibitors of cellular proliferation | |
CY1107747T1 (el) | Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
MXPA05011707A (es) | Dihidroquinazolinas sustituidas con propiedades antivirales. | |
TW200519096A (en) | Quinazoline analogs as receptor tyrosine kinase inhibitors | |
UA85087C2 (en) | Monocyclic heterocycles as kinase inhibitors | |
ES2249309T3 (es) | Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa. | |
MXPA05013905A (es) | Compuestos de quinazolinona sustituidos por arilamina. | |
MEP6708A (xx) | Derivati n/tiayol/2/yl/benyamida | |
YU22802A (sh) | Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina | |
ATE265418T1 (de) | Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine |